Chia sẻ
))
How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
Interview with Dr. Kristin Yarema, President of Cell Therapy at Poseida Therapeutics
Manage episode 378120752 series 2900042
Nội dung được cung cấp bởi Xtalks. Tất cả nội dung podcast bao gồm các tập, đồ họa và mô tả podcast đều được Xtalks hoặc đối tác nền tảng podcast của họ tải lên và cung cấp trực tiếp. Nếu bạn cho rằng ai đó đang sử dụng tác phẩm có bản quyền của bạn mà không có sự cho phép của bạn, bạn có thể làm theo quy trình được nêu ở đây https://vi.player.fm/legal.
In this episode, Vera interviews Dr. Kristin Yarema, President of Cell Therapy at Poseida Therapeutics, about Poseida’s cell therapy approach and technologies.
In April 2023, Dr. Yarema became the President of Cell Therapy at Poseida. She brings a wealth of knowledge from the biopharmaceutical realm, with expertise in oncology and allogeneic T-cell immunotherapy.
Poseida is a clinical-stage biopharmaceutical firm that utilizes its unique non-viral gene engineering methods to develop innovative cell and gene therapies. With their extensive genetic engineering capabilities, they are paving the way for potentially better and safer treatments for conditions including blood cancers such as multiple myeloma, solid tumors like breast and ovarian cancer, and rare genetic liver diseases.
In this episode, Dr. Yarema talks about the advantages of “off the shelf” or allogeneic CAR-T cell therapy vs. autologous cell therapy — and what makes Poseida’s approach unique.
Dr. Yarema discusses Poseida’s two Phase I programs in collaboration with Roche, highlighting the strategic partnership's significance for Poseida.
She shares what Poseida is looking forward to with the Investigational New Drug (IND) clearance for the first dual CAR program targeting CD19 and CD20 for the treatment of B-cell malignancies.
Dr. Yarema also discusses how the recent $50 million strategic investment from Astellas Pharma in Poseida signifies a notable endorsement and potential growth trajectory for the company.
The episode concludes with Dr. Yarema sharing her thoughts about the promise of allogeneic CAR-T cell therapy for patients.
For more life science and medical device content, visit the Xtalks Vitals homepage.
Follow Us on Social Media
Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
139 tập
